Who Pays My Doctor?

Healthcare provider profile · identity verified

Kent Galen Mcdaniel, M.D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · GLEN ALLEN, VA · NPI 1871640789

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Kent Galen Mcdaniel, M.D. received $398,590.96 in general payments during 2025 across 390 reported records.

Otsuka America Pharmaceutical, Inc. accounted for 24.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 10 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Caplyta, Ingrezza, Invega Trinza, Rexulti.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA TRINZA as an associated drug or biological on 8191 records involving 2146 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Invega Trinza by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ingrezza by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Abilify Maintena by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$398,590.96

390 reported records · 6 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $98,215.2724.6%922025
Janssen Pharmaceuticals, Inc Unresolved — no canonical attribution shown $84,375.2421.2%952025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $79,299.0519.9%802025
Teva Pharmaceuticals USA, Inc. Unresolved — no canonical attribution shown $59,434.2314.9%512025
Neurocrine BioSciences, Inc. Unresolved — no canonical attribution shown $59,044.1514.8%472025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $18,223.024.6%252025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$349,752.00101
Travel and Lodging$27,783.52178
Consulting Fee$14,200.004
Food and Beverage$6,855.44107

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
INVEGA SUSTENNA
Normalized: invega sustenna		 Drug Janssen Pharmaceuticals, Inc $84,375.24 95 2025
Source payment records
INVEGA TRINZA
Normalized: invega trinza		 Drug Janssen Pharmaceuticals, Inc $84,105.43 93 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $79,299.05 80 2025
Source payment records
ABILIFY ASIMTUFII
Normalized: abilify asimtufii		 Drug Otsuka America Pharmaceutical, Inc. $79,199.44 72 2025
Source payment records
ABILIFY MAINTENA
Normalized: abilify maintena		 Drug Otsuka America Pharmaceutical, Inc. $79,199.44 72 2025
Source payment records
INGREZZA
Normalized: ingrezza		 Drug Neurocrine BioSciences, Inc. $59,044.15 47 2025
Source payment records
UZEDY
Normalized: uzedy		 Drug Teva Pharmaceuticals USA, Inc. $39,875.61 32 2025
Source payment records
AUSTEDO XR
Normalized: austedo xr		 Drug Teva Pharmaceuticals USA, Inc. $19,558.62 19 2025
Source payment records
REXULTI
Normalized: rexulti		 Drug Otsuka America Pharmaceutical, Inc. $19,015.83 20 2025
Source payment records
COBENFY
Normalized: cobenfy		 Drug E.R. Squibb & Sons, L.L.C. $18,223.02 25 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
ABILIFY MAINTENA
abilify maintena		 2025 Abilify Maintena 2024 15
Beneficiary count suppressed		 exact normalized Medicare Part D
CAPLYTA
caplyta		 2025 Caplyta 2024 12
Beneficiary count suppressed		 exact normalized Medicare Part D
INGREZZA
ingrezza		 2025 Ingrezza 2024 14
Beneficiary count suppressed		 exact normalized Medicare Part D
INVEGA TRINZA
invega trinza		 2025 Invega Trinza 2024 22
Beneficiary count suppressed		 exact normalized Medicare Part D
REXULTI
rexulti		 2025 Rexulti 2024 26
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
Exact reporting entity; no affiliate inference		 2025 CAPLYTA
open payments reported associated product		 CMS Open Payments — General Payments
211855 supporting records · 46143 recipient NPIs · example record 1241243071 		Caplyta · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS
Janssen Pharmaceuticals, Inc
Exact reporting entity; no affiliate inference		 2025 Caplyta
open payments reported associated product		 CMS Open Payments — General Payments
11 supporting records · 9 recipient NPIs · example record 1174547314 		Caplyta · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS
Janssen Pharmaceuticals, Inc
Exact reporting entity; no affiliate inference		 2025 INVEGA TRINZA
open payments reported associated product		 CMS Open Payments — General Payments
8191 supporting records · 2146 recipient NPIs · example record 1174223262 		Invega Trinza · 2024
Exact normalized brand match · 1 Part D row		 22 suppressed by CMS
Neurocrine BioSciences, Inc.
Exact reporting entity; no affiliate inference		 2025 INGREZZA
open payments reported associated product		 CMS Open Payments — General Payments
126456 supporting records · 27390 recipient NPIs · example record 1242766729 		Ingrezza · 2024
Exact normalized brand match · 1 Part D row		 14 suppressed by CMS
Otsuka America Pharmaceutical, Inc.
Exact reporting entity; no affiliate inference		 2025 ABILIFY MAINTENA
open payments reported associated product		 CMS Open Payments — General Payments
27924 supporting records · 10497 recipient NPIs · example record 1227267721 		Abilify Maintena · 2024
Exact normalized brand match · 1 Part D row		 15 suppressed by CMS
Otsuka America Pharmaceutical, Inc.
Exact reporting entity; no affiliate inference		 2025 REXULTI
open payments reported associated product		 CMS Open Payments — General Payments
160756 supporting records · 46288 recipient NPIs · example record 1227267708 		Rexulti · 2024
Exact normalized brand match · 1 Part D row		 26 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
ClozapineClozapine233suppressed
OlanzapineOlanzapine12916
RisperidoneRisperidone12712
MirtazapineMirtazapine92suppressed
Escitalopram OxalateEscitalopram Oxalate77suppressed
Divalproex Sodium ErDivalproex Sodium76suppressed
ClonazepamClonazepam63suppressed
Sertraline HclSertraline Hcl49suppressed
HaloperidolHaloperidol45suppressed
Hydroxyzine PamoateHydroxyzine Pamoate41suppressed
LybalviOlanzapine/Samidorphan Malate41suppressed
Trazodone HclTrazodone Hcl39suppressed
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine36suppressed
AripiprazoleAripiprazole33suppressed
Fluvoxamine MaleateFluvoxamine Maleate32suppressed
Quetiapine FumarateQuetiapine Fumarate27suppressed
Lithium Carbonate ErLithium Carbonate26suppressed
RexultiBrexpiprazole26suppressed
Fluphenazine HclFluphenazine Hcl25suppressed
Bupropion Hcl SrBupropion Hcl22suppressed
Invega TrinzaPaliperidone Palmitate22suppressed
Lurasidone HclLurasidone Hcl22suppressed
Venlafaxine Hcl ErVenlafaxine Hcl22suppressed
Tamsulosin HclTamsulosin Hcl21suppressed
Prazosin HclPrazosin Hcl20suppressed
Trihexyphenidyl HclTrihexyphenidyl Hcl20suppressed
Bupropion XlBupropion Hcl18suppressed
Fluphenazine DecanoateFluphenazine Decanoate18suppressed
OmeprazoleOmeprazole18suppressed
Atorvastatin CalciumAtorvastatin Calcium17suppressed
GabapentinGabapentin17suppressed
PerphenazinePerphenazine16suppressed
Abilify MaintenaAripiprazole15suppressed
Carbidopa-LevodopaCarbidopa/Levodopa15suppressed
Propranolol HclPropranolol Hcl15suppressed
Carbamazepine ErCarbamazepine14suppressed
Doxepin HclDoxepin Hcl14suppressed
Fluoxetine HclFluoxetine Hcl14suppressed
IngrezzaValbenazine Tosylate14suppressed
Metformin HclMetformin Hcl14suppressed
ZaleplonZaleplon14suppressed
Buspirone HclBuspirone Hcl13suppressed
Chlorpromazine HclChlorpromazine Hcl13suppressed
Esomeprazole MagnesiumEsomeprazole Magnesium13suppressed
LevetiracetamLevetiracetam13suppressed
CaplytaLumateperone Tosylate12suppressed
TemazepamTemazepam11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $398,590.96 · 390 records Otsuka America Pharmaceutical, Inc. ABILIFY ASIMTUFII, ABILIFY MAINTENA, AUSTEDO XR, CAPLYTA, COBENFY, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, REXULTI, UZEDY 6 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error